Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant
Clinical trial NCT05526313 · COMPLETED
Trial details
- NCT number
- NCT05526313
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-10
- Primary completion
- 2022-09-07
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.